Jefferies analyst Dennis Ding reiterated a Buy rating and $45.00 price target on NewAmsterdam Pharma Co NV (NASDAQ: NAMS).The analyst ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments